{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:43:49Z","timestamp":1787499829067,"version":"build-2736575974"},"reference-count":41,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Breast cancer is the most common malignancy in women of reproductive age, and treatment advances have heightened the importance of fertility preservation (FP) for young patients. Despite heterogeneity across subtypes\u2014hormone receptor-positive (HR+), HER2-positive, triple-negative (TNBC), and BRCA1\/2-associated\u2014existing guidelines lack subtype-specific FP guidance. Methods: This systematic review compared FP strategies across subtypes, identified subtype-specific challenges, and proposed pathways toward precision oncofertility care. PubMed, Scopus, and Web of Science were searched following PRISMA guidelines for English-language studies from 2004 to 2024. Results: After screening 1837 records, 19 studies met eligibility criteria (2 RCTs, 17 cohort studies); 11 of 17 non-randomized studies were at low overall risk of bias, and 6 at moderate risk due to confounding. Discussion: COS using letrozole- or tamoxifen-modified protocols was feasible, yielding 8\u201314 mature oocytes per cycle with reduced estradiol exposure suitable for HR+ disease. Evidence was strongest for HR+ patients; TNBC and HER2+ data were more limited, with some studies noting reduced ovarian reserve. GnRH agonists during chemotherapy reduced ovarian failure rates and improved post-treatment recovery, most consistently in hormone receptor-negative disease. BRCA1\/2 carriers showed broadly comparable FP outcomes to non-carriers, though BRCA1-positive patients had modestly reduced oocyte yields in some studies with inconsistent results. Conclusions: Among studies with medium-term follow-up (3\u20135.5 years), no significant increase in recurrence or mortality attributable to FP was identified; long-term data beyond 5 years remain sparse. Substantial heterogeneity precluded meta-analysis; all synthesis is narrative. Standardized outco reporting and larger prospective subtype-stratified studies are required to establish precision oncofertility recommendations.<\/jats:p>","DOI":"10.3390\/cancers18121896","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:48:35Z","timestamp":1781138915000},"page":"1896","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tailoring Oncofertility to Breast Cancer Subtype: A Systematic Review of Fertility Preservation Strategies in Premenopausal Women"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1843-5796","authenticated-orcid":false,"given":"Maryam Garba","family":"Oloriegbe","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9496-9754","authenticated-orcid":false,"given":"Olena","family":"Bolgova","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2356-9069","authenticated-orcid":false,"given":"Rasha","family":"Alissa","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa","family":"Abdelmeguid","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamida Garba","family":"Oloriegbe","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0597-2510","authenticated-orcid":false,"given":"Umaiza","family":"Rehan","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1159-4573","authenticated-orcid":false,"given":"Volodymyr","family":"Mavrych","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Freihat, O., Sipos, D., and Kovacs, A. (2025). Global burden and projections of breast cancer incidence and mortality to 2050: A comprehensive analysis of GLOBOCAN data. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1622954"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, W., Sun, Y., Li, J., Bai, H., Ren, C., Feng, Y., and Wang, S. (2025). Global, regional, and national burden of breast cancer in young women from 1990 to 2021: Findings from the global burden of disease study 2021. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14416-1"},{"key":"ref_4","unstructured":"(2025, November 15). Breast Recent Trends in SEER Age-Adjusted Incidence Rates, 2000\u20132022, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"ref_5","first-page":"e2200354","article-title":"Improved Survival of Young Patients with Breast Cancer 40 Years and Younger at Diagnosis","volume":"9","author":"Khalil","year":"2023","journal-title":"JCO Glob. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1038\/s41598-025-91197-4","article-title":"Prevalence and impact of fertility preservation among young women with breast cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17588359251341210","DOI":"10.1177\/17588359251341210","article-title":"Fertility preservation in young patients with breast cancer: Insights from the Gemme Dormienti network","volume":"17","author":"Gentile","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4048\/jbc.2023.26.e28","article-title":"Fertility Preservation in Young Women with Breast Cancer: A Review","volume":"26","author":"Hong","year":"2023","journal-title":"J. Breast Cancer"},{"key":"ref_9","unstructured":"(2021). Committee of Diagnosis Treatment and Fertility Management of Chinese Young Breast Cancer Patients. Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients. J. Natl. Cancer Cent., 1, 23\u201330."},{"key":"ref_10","first-page":"17455057221114268","article-title":"Twenty-first century oocyte cryopreservation-in vitro maturation of immature oocytes from ovarian tissue cryopreservation in cancer patients: A systematic review","volume":"18","author":"Sugishita","year":"2022","journal-title":"Women\u2019s Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility Preservation in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Oktay","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hage, A.M., Gebert, P., Blohmer, J.-U., Hedayati, E., Speiser, D., and Karsten, M.M. (2024). Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status. Cancers, 16.","DOI":"10.3390\/cancers16040738"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"pkac045","DOI":"10.1093\/jncics\/pkac045","article-title":"Chemotherapy Regimens Received by Women with BRCA1\/2 Pathogenic Variants for Early Stage Breast Cancer Treatment","volume":"6","author":"Kurian","year":"2022","journal-title":"JNCI Cancer Spectr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103776","DOI":"10.1016\/j.breast.2024.103776","article-title":"Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up","volume":"77","author":"Dezellus","year":"2024","journal-title":"Breast"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/09513590.2021.2002294","article-title":"Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation","volume":"38","author":"Kim","year":"2022","journal-title":"Gynecol. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.fertnstert.2015.07.1162","article-title":"BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles","volume":"104","author":"Shapira","year":"2015","journal-title":"Fertil. Steril."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.fertnstert.2018.10.014","article-title":"BRCA carriers have similar reproductive potential at baseline to noncarriers: Comparisons in cancer and cancer-free cohorts undergoing fertility preservation","volume":"111","author":"Gunnala","year":"2019","journal-title":"Fertil. Steril."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10815-019-01658-9","article-title":"Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer","volume":"37","author":"Porcu","year":"2020","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10815-021-02273-3","article-title":"Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: The TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial","volume":"38","author":"Letourneau","year":"2021","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/09513590.2013.819083","article-title":"Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?","volume":"29","author":"Revelli","year":"2013","journal-title":"Gynecol. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Prokurotaite, E., Condorelli, M., Dechene, J., Bouziotis, J., Lambertini, M., and Demeestere, I. (2023). Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women. Life, 13.","DOI":"10.3390\/life13040930"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"El Moujahed, L., Philis, R., Grynberg, M., Laot, L., Mur, P., Amsellem, N., Mayeur, A., Benoit, A., Rakrouki, S., and Sifer, C. (2023). Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in BRCA-Pathogenic-Variant-Positive Breast Cancer Patients. Cancers, 15.","DOI":"10.3390\/cancers15030895"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s10815-020-01944-x","article-title":"COH outcomes in breast cancer patients for fertility preservation: A comparison with the expected response by age","volume":"37","author":"Malacarne","year":"2020","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jfma.2024.08.031","article-title":"Ovarian stimulation response and fertility outcomes in patients with breast cancer across different stages, grades, and hormone receptor status for fertility preservation","volume":"124","author":"Liu","year":"2025","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1933719117728800","article-title":"Ovarian Stimulation in Patients with Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes","volume":"25","author":"Turan","year":"2018","journal-title":"Reprod. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-020-05598-2","article-title":"Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience","volume":"181","author":"Vriens","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.23.02292","article-title":"Fertility Preservation and Assisted Reproduction in Patients with Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy","volume":"42","author":"Azim","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lee, D.-Y., Kim, J.-Y., Yu, J., and Kim, S.W. (2020). Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00863"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.7150\/jca.31859","article-title":"GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer","volume":"10","author":"Zhong","year":"2019","journal-title":"J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10815-022-02486-0","article-title":"Hereditary breast cancer and fertility preservation outcomes","volume":"39","author":"Arab","year":"2022","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/humrep\/dey358","article-title":"BRCA1\/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro","volume":"34","author":"Grynberg","year":"2019","journal-title":"Hum. Reprod."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/humrep\/deac109","article-title":"Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation","volume":"37","author":"Raad","year":"2022","journal-title":"Hum. Reprod."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bonardi, B., Massarotti, C., Bruzzone, M., Goldrat, O., Mangili, G., Anserini, P., Spinaci, S., Arecco, L., Del Mastro, L., and Ceppi, M. (2020). Efficacy and Safety of Controlled Ovarian Stimulation with or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.574669"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","article-title":"Association of BRCA1 Mutations with Occult Primary Ovarian Insufficiency: A Possible Explanation for the Link Between Infertility and Breast\/Ovarian Cancer Risks","volume":"28","author":"Oktay","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1210\/jc.2017-00765","article-title":"Ovarian Aging in Women with BRCA Germline Mutations","volume":"102","author":"Lin","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1095\/biolreprod.115.132290","article-title":"BRCA Mutations, DNA Repair Deficiency, and Ovarian Aging","volume":"93","author":"Oktay","year":"2015","journal-title":"Biol. Reprod."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Scavone, G., Ottonello, S., Blondeaux, E., Arecco, L., Scaruffi, P., Stigliani, S., Cardinali, B., Borea, R., Paudice, M., and Vellone, V.G. (2023). The Role of Cyclin-Dependent Kinases (CDK) 4\/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition. Cancers, 15.","DOI":"10.3390\/cancers15204923"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1896\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:58:10Z","timestamp":1781139490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121896"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121896","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}